Drugs/Warning Letter·FDA Warning Letters

Warning Letter — Suretec Innovations, LLC

MediumPublished Aug 18, 2026· AI-analyzed Aug 19, 2026View original FDA source

AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.

What happened

The FDA issued a Warning Letter to Suretec Innovations, LLC on August 13, 2026, following an evaluation by the Center for Drug Evaluation and Research (CDER).

Who it affects

This affects Suretec Innovations, LLC and its personnel responsible for drug manufacturing, quality control, and regulatory compliance.

Why it matters

The issuance of a Warning Letter by CDER indicates significant deviations from regulatory requirements. Failure to address these concerns may lead to further enforcement actions, such as seizure, injunction, or restrictions on product distribution. The source does not specify the exact nature of the violations, but typically these involve cGMP non-compliance.

Practical takeaway

Review manufacturing protocols to ensure alignment with current Good Manufacturing Practice (cGMP) standards and prepare for immediate corrective action planning regarding the specific deficiencies cited in the CDER warning letter.

FDA source material

FDA Warning Letter issued to: Suretec Innovations, LLC. 08/13/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/suretec-innovations-llc-730122-08132026

Open in openFDA / FDA.gov

AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.

Warning Letter — Suretec Innovations, LLC

More from Drugs